Novo Nordisk shares gain 4.5% on fourth-quarter profit beat, Wegovy sales jump

Shares of Novo Nordisk rose 4.5% after reporting a better-than-expected net profit in the fourth quarter, driven by strong demand for its obesity drug Wegovy. The Danish pharmaceutical company’s net profit increased by 29% annually to 28.23 billion Danish kroner in Q4, surpassing estimates. Despite a 30% growth in overall sales, Novo Nordisk forecasted a slight slowdown in sales growth for 2025 due to intensifying competition and pricing pressure in the Diabetes and Obesity care market.

Full Article